3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
View Patent ↗The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid
1. A method of treating, or inhibiting a ras-associated disease selected from lung cancer, lung adenocarcinoma, pancreatic cancers, pancreatic carcinoma, exocrine pancreatic carcinoma, colon cancers, colorectal carcinomas, colon adenocarcinoma, colon adenoma, myeloid leukemias, acute myelogenous leukemia (AML), thyroid cancer, thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer, prostate cancer, neuro-fibromatosis, restenosis, endometriosis, and psoriasis, and controlling metastasis, suppressing angiogenesis, and inducing apoptosis, by inhibiting farnesyl-protein transferase(FPTase) enzyme in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I)
wherein:
R 1 is a moiety
R 2 is a moiety
n is an integer of 1 and 3 to 9;
m is an integer of 0 or 2;
R 3 and R 4 are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethoxy, phenoxy said phenoxy being optionally mono or disubstituted with substituents independently selected from alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethyl, trifluoromethoxy, methanesulphonyl, phenyl, phenoxy, and benzyloxy, said benzyloxy being optionally mono or disubstituted with substituents independently selected from alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethyl, trifluoromethoxy, methanesulphonyl, phenyl, phenoxy, and benzyloxy;
R 5 , and R 6 , are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, halogen, nitro, phenyl said phenyl being optionally mono or disubstituted with substituents independently selected from alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethyl, trifluoromethoxy, methanesulphonyl, phenyl, phenoxy, and benzyloxy, said phenoxy being optionally mono or disubstituted with substituents independently selected from alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethyl, trifluoromethoxy, methanesulphonyl, phenyl, phenoxy, and benzyloxy, trifluoromethyl, trifluoromethoxy, and methanesulphonyl;
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R 1 is 4-methoxyphenyl and R 2 is 4-chlorophenyl or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 wherein n is 3 and m is 2 or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 , where the compound is 3-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(4-methylbenzenesulfonyl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.
5. The method according to claim 1 , where the compound is 3-[3-4-Chlorophenyl)prop-2-ynyl]-3-(4-methylbenzenesulfonyl)-pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 wherein the ras-associated disease in mammals is selected from the group consisting of cancers of the pancreas, breast, lung, colon, epidermis, prostate, bladder, thyroid, myelodysplastic tumors and myeloid leukemia.
7. The method of claim 1 wherein the ras-associated disease in mammals is selected from metastasis, suppressing angiogenesis, and inducing apoptosis.
8. The method of claim 1 wherein the ras-associated proliferative disease in mammals is restenosis, neurofibromatosis, endometriosis, and psoriasis.